• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial.

作者信息

Inoue Tadahisa, Kato Akihisa, Yoshida Michihiro, Kitada Tomoya, Kitano Rena, Naitoh Itaru

机构信息

Department of Gastroenterology, Aichi Medical University, Nagakute, Japan.

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):673-675. doi: 10.21037/hbsn-2025-315. Epub 2025 Jul 24.

DOI:10.21037/hbsn-2025-315
PMID:40893742
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393121/
Abstract
摘要

相似文献

1
Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial.转移性胰腺癌中疗效与耐受性的平衡：来自ALPACA试验的经验教训。
Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):673-675. doi: 10.21037/hbsn-2025-315. Epub 2025 Jul 24.
2
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.转移性胰腺癌诱导治疗后交替吉西他滨加 nab-紫杉醇和单纯吉西他滨与连续吉西他滨加 nab-紫杉醇治疗（ALPACA）：一项多中心、随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16.
3
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.LOAd703，一种基于溶瘤病毒的免疫刺激基因治疗药物，联合化疗用于不可切除或转移性胰腺癌（LOKON001）：来自非随机、单中心、1/2 期研究臂 1 的结果。
Lancet Oncol. 2024 Apr;25(4):488-500. doi: 10.1016/S1470-2045(24)00079-2.
4
Chemotherapy and radiotherapy for advanced pancreatic cancer.晚期胰腺癌的化疗与放疗
Cochrane Database Syst Rev. 2024 Dec 5;12(12):CD011044. doi: 10.1002/14651858.CD011044.pub3.
5
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.不可切除的局部晚期或转移性胰腺癌一线化疗方案的比较：一项系统评价和贝叶斯网络荟萃分析
Lancet Oncol. 2024 Dec;25(12):1655-1665. doi: 10.1016/S1470-2045(24)00511-4. Epub 2024 Nov 11.
6
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.Halo202：PEGPH20 联合 Nab-紫杉醇/吉西他滨与 Nab-紫杉醇/吉西他滨治疗未经治疗的转移性胰腺导管腺癌患者的随机 II 期研究。
J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.
7
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.在初治转移性胰腺导管腺癌患者中，NALIRIFOX与白蛋白结合型紫杉醇+吉西他滨相比的健康相关生活质量和体能状态：NAPOLI 3试验结果
ESMO Open. 2025 Aug;10(8):105534. doi: 10.1016/j.esmoop.2025.105534. Epub 2025 Aug 5.
8
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.改良氟尿嘧啶、亚叶酸钙、伊立替康和奥沙利铂或S-1、伊立替康和奥沙利铂对比纳米白蛋白结合型紫杉醇+吉西他滨治疗转移性或复发性胰腺癌（GENERATE，JCOG1611）：一项随机、开放标签的II/III期试验
J Clin Oncol. 2025 Jul 28:JCO2400936. doi: 10.1200/JCO.24.00936.
9
Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.不同化疗方案治疗晚期或转移性胰腺癌的疗效和毒性：一项网状荟萃分析。
J Cell Biochem. 2018 Jan;119(1):511-523. doi: 10.1002/jcb.26210. Epub 2017 Jul 17.
10
GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer.GABRINOX - 2方案：一项法国的前瞻性多中心随机II期试验，评估吉西他滨/纳米白蛋白结合型紫杉醇序贯FOLFIRINOX方案与单纯FOLFIRINOX方案作为转移性胰腺癌一线治疗的疗效。
BMJ Open. 2025 Aug 16;15(8):e104228. doi: 10.1136/bmjopen-2025-104228.

本文引用的文献

1
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.转移性胰腺癌诱导治疗后交替吉西他滨加 nab-紫杉醇和单纯吉西他滨与连续吉西他滨加 nab-紫杉醇治疗（ALPACA）：一项多中心、随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16.
2
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
评估转移性胰腺癌一线两种序贯治疗的随机II期试验：PANOPTIMOX-PRODIGE 35试验结果
J Clin Oncol. 2021 Oct 10;39(29):3242-3250. doi: 10.1200/JCO.20.03329. Epub 2021 Jul 21.
4
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.纳米白蛋白结合型紫杉醇联合吉西他滨与吉西他滨用于转移性胰腺癌患者的剂量调整及疗效：III期MPACT试验
J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.
5
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.白蛋白结合型紫杉醇联合吉西他滨治疗转移性胰腺癌：III 期临床试验的长期生存结果。
J Natl Cancer Inst. 2015 Jan 31;107(2). doi: 10.1093/jnci/dju413. Print 2015 Feb.
6
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌可提高生存率。
N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.